公开(公告)号：EP2860188A4

公开(公告)日：2016-04-27

申请号：EP13804161

申请日：2013-06-06

申请人： UNIV XIAMEN ,  XIAMEN INNOVAX BIOTECH CO LTD

发明人： YUAN QUAN ,  ZHANG TIANYING ,  LUO WENXIN ,  CHEN YIXIN ,  ZHANG JUN ,  XIA NINGSHAO

IPC分类号： C07K14/02 ,  A61K39/29 ,  C07K16/28

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/6037 ,  C07K7/06 ,  C07K16/082 ,  C07K2317/24 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/00034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12P21/02 ,  G01N33/56983 ,  G01N2333/02

摘要： The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositons for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.

公开(公告)号：EP2716661A4

公开(公告)日：2015-01-14

申请号：EP12793630

申请日：2012-06-01

申请人： UNIV XIAMEN ,  XIAMEN INNOVAX BIOTECH CO LTD

发明人： LI SHAOWEI ,  SONG CUILING ,  YANG CHUNYAN ,  GU YING ,  LUO WENXIN ,  XIA NINGSHAO

IPC分类号： C07K19/00 ,  A61K38/16 ,  A61K47/48 ,  A61P1/16 ,  A61P31/14 ,  A61P31/16 ,  C12N15/62

CPC分类号： A61K39/39 ,  A61K38/00 ,  A61K39/05 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55544 ,  A61K2039/6037 ,  C07K14/005 ,  C07K14/34 ,  C07K2319/03 ,  C07K2319/55 ,  C07K2319/74 ,  C12N7/00 ,  C12N9/1048 ,  C12N15/62 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2770/28122 ,  C12N2770/28134

摘要： Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.

摘要翻译： 在本发明中提供了作为融合蛋白中的佐剂的白喉毒素无毒突变体CRM197或其片段，以及其用于增强与其融合的靶蛋白（例如HEV衣壳蛋白）的免疫原性的用途，或 流感病毒M2蛋白或其免疫原性片段。 还提供了增强靶蛋白的免疫原性的方法，其包括将CRM197或其片段与靶蛋白的融合表达形成融合蛋白。 还提供了包含CRM197或其片段和靶蛋白的融合蛋白，CRM197或其片段增强靶蛋白的免疫原性。 本发明还提供编码融合蛋白的分离的核酸，包含所述核酸的构建体和载体，以及包含所述核酸的宿主细胞。

公开(公告)号：EP2174957A4

公开(公告)日：2011-12-14

申请号：EP08772961

申请日：2008-06-16

申请人： UNIV XIAMEN ,  YANG SHENG TANG COMPANY LTD

发明人： CHEN YIXIN ,  LUO WENXIN ,  ZHANG JUN ,  XIA NINGSHAO ,  GUAN YI ,  CHEN HONGLIN

IPC分类号： C07K16/18 ,  A61K38/08 ,  A61K38/10 ,  A61K39/395 ,  A61P31/16 ,  C07K7/06 ,  C07K7/08 ,  C07K14/11 ,  C07K16/10 ,  C07K16/46 ,  C12N5/12 ,  C12N15/13 ,  C12N15/63 ,  G01N33/53 ,  G01N33/569

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C12N2760/16111 ,  G01N33/56983 ,  G01N2333/11

公开(公告)号：EP2982691A4

公开(公告)日：2016-11-23

申请号：EP14778269

申请日：2014-04-02

申请人： UNIV XIAMEN

发明人： CHEN YIXIN ,  ZHENG QINGBING ,  LI RUI ,  SHEN CHENGUANG ,  KE SHAOJUN ,  LUO WENXIN ,  CHEN HONGLIN ,  XIA NINGSHAO

IPC分类号： C07K16/10 ,  A61K39/42 ,  A61P31/16 ,  C12N5/20 ,  C12N15/13 ,  C12N15/63

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/11 ,  G01N2469/10

摘要： The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.

公开(公告)号：EP2154147A4

公开(公告)日：2011-11-02

申请号：EP08748431

申请日：2008-04-29

申请人： BEIJING WANTAI BIOLOGICAL PHARMACY ENTPR CO LTD ,  UNIV XIAMEN

发明人： GU YING ,  LI SHAOWEI ,  WEI MINXI ,  XIAN YANGLING ,  LUO WENXIN ,  XIA NINGSHAO

IPC分类号： C07K14/025 ,  A61K39/12 ,  A61P15/02 ,  A61P31/20 ,  A61P35/00 ,  C07K1/18 ,  C12N7/02 ,  C12N15/37

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20034